WHO-defined myelodysplastic syndrome with isolated del(5q) in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations

M. M. Patnaik, T. L. Lasho, C. M. Finke, N. Gangat, D. Caramazza, S. G. Holtan, A. Pardanani, R. A. Knudson, R. P. Ketterling, D. Chen, J. D. Hoyer, C. A. Hanson, A. Tefferi

Research output: Contribution to journalArticle

74 Scopus citations

Abstract

The 2008 World Health Organization (WHO) criteria were used to identify 88 consecutive Mayo Clinic patients with myelodysplastic syndrome with isolated del(5q) (median age 74 years; 60 females). In all, 60 (68%) patients were followed up to the time of their death. Overall median survival was 66 months; leukemic transformation was documented in five (5.7%) cases. Multivariable analysis identified age 70 years (P0.01), transfusion need at diagnosis (P0.04) and dysgranulopoiesis (P0.02) as independent predictors of shortened survival; the presence of zero (low risk), one (intermediate risk) or 2 (high risk) risk factors corresponded to median survivals of 102, 52 and 27 months, respectively. Janus kinase 2 (JAK2), thrombopoietin receptor (MPL), isocitrate dehydrogenase 1 (IDH1) and IDH2 mutational analysis was performed on archived bone marrows in 78 patients; JAK2V617F and MPLW515L mutations were shown in five (6.4%) and three (3.8%) patients, respectively, and did not seem to affect phenotype or prognosis. IDH mutations were not detected. Survival was not affected by serum ferritin and there were no instances of death directly related to iron overload. The current study is unique in its strict adherence to WHO criteria for selecting study patients and providing information on long-term survival, practical prognostic factors, baseline risk of leukemic transformation and the prevalence of JAK2, MPL and IDH mutations.

Original languageEnglish (US)
Pages (from-to)1283-1289
Number of pages7
JournalLeukemia
Volume24
Issue number7
DOIs
StatePublished - Jul 2010

Keywords

  • 5q-
  • ferritin
  • iron
  • isocitrate dehydrogenase
  • prognosis

Fingerprint Dive into the research topics of 'WHO-defined myelodysplastic syndrome with isolated del(5q) in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations'. Together they form a unique fingerprint.

  • Cite this

    Patnaik, M. M., Lasho, T. L., Finke, C. M., Gangat, N., Caramazza, D., Holtan, S. G., Pardanani, A., Knudson, R. A., Ketterling, R. P., Chen, D., Hoyer, J. D., Hanson, C. A., & Tefferi, A. (2010). WHO-defined myelodysplastic syndrome with isolated del(5q) in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia, 24(7), 1283-1289. https://doi.org/10.1038/leu.2010.105